28 Supported by research
Approximately 75 million Americans have a single copy of APOE4, and 7 million Americans have two copies of APOE4.
"75 million Americans have a single copy; 7 million Americans have two copies." (said at 0:11:08)
Epidemiological and population genetics studies in the United States establish that approximately 20% to 25% of the US population carries a single APOE ε4 allele (heterozygotes), and approximately 2% carries two copies (homozygotes). Applied to the total US population (roughly 335 million), 20% to 25% corresponds to approximately 67 to 84 million Americans with a single copy of APOE4, and ~2% corresponds to approximately 6.7 to 7 million Americans with two copies (APOE4/4). The guest's figures of 75 million single-copy carriers and 7 million homozygotes align closely with standard epidemiological estimates.
Ruth Itzhaki demonstrated the colocalization of herpes simplex virus (HSV) with beta-amyloid in human brain specimens.
"In fact, I think that Ruth Itzhaki's work kind of inferred that when she demonstrated colocalization of HSV with beta-amyloid in human specimens." (said at 0:12:17)
Ruth Itzhaki and her research group demonstrated the colocalization of herpes simplex virus type 1 (HSV-1) DNA within amyloid plaques in human brain tissue specimens (Wozniak et al., 2009, J Pathol). Using in situ polymerase chain reaction combined with immunohistochemistry and thioflavin S staining, they found that 90% of amyloid plaques in Alzheimer's disease brain tissue contained HSV-1 DNA, with 72% of the viral DNA specifically associated with plaques. Because this finding is based on observational human post-mortem tissue studies, the certainty of the overall body of evidence regarding causal etiology is low.
Beta-amyloid, phosphorylated tau, and alpha-synuclein are antimicrobial peptides.
"there's no question amyloid is part of the response. It is an antimicrobial peptide. And guess what? p-tau is also antimicrobial. Guess what? Alpha-synuclein of Parkinson's and Lewy body and MSA, that's also antimicrobial." (said at 0:16:06)
The speaker's statement accurately reflects published research demonstrating that amyloid-beta, phosphorylated tau, and alpha-synuclein exhibit antimicrobial activity and act as effector molecules of the innate immune system. In vitro and animal models have identified antimicrobial peptide (AMP) characteristics for amyloid-beta (entrapping bacteria and viruses), phosphorylated tau (neutralizing herpes simplex virus 1), and alpha-synuclein (restricting viral and bacterial replication and modulating immune responses).
- supports: Upregulation of α-synuclein following immune activation: Possible trigger of Parkinson's d… (Neurobiology of disease 2022) · cited 79x in the literature
"Alpha-synuclein (α-syn) has been suggested to have many functions including, vesicle transport in neurons, transcriptional regulator, modulator of immune cell maturation and response, and a role as an antimicrobial peptide." (abstract, passage verified)
pubmedfull study (doi) - supports: Infectious origin of Alzheimer's disease: Amyloid beta as a component of brain antimicrobi… (PLoS pathogens 2022) · cited 87x in the literature
"We show evidence from the current literature that amyloid beta, traditionally viewed as pathological, actually acts as an antimicrobial peptide, protecting the brain against pathogens." (abstract, passage verified)
pubmedfull study (doi) - supports: Phosphorylated tau exhibits antimicrobial activity capable of neutralizing herpes simplex … (Nature neuroscience 2026) · cited 18x in the literature
"We previously showed that the principal component of senile plaques, amyloid beta (Aβ), is an antimicrobial peptide capable of binding and entrapping microbial pathogens. Here we show that tau is hyperphosphorylated in neurons in response to viral infection and can neutralize herpes simplex virus 1 (HSV-1) infectivity by directly binding to viral capsids." (abstract, passage verified)
pubmedfull study (doi)
Blood levels of phosphorylated tau, specifically p-tau217, strongly correlate with brain amyloid burden and ongoing neuropathology.
"And the striking relationship between phospho-tau levels in the blood—specifically p-tau217 in the blood—and the amount of amyloid in the brain and ongoing pathology in the brain." (said at 0:24:10)
Large prospective cohort and diagnostic validation studies demonstrate that blood levels of tau phosphorylated at threonine 217 (plasma p-tau217 and %p-tau217) correlate strongly with brain amyloid-beta deposition (measured by amyloid PET) and neurofibrillary tau tangles (measured by tau PET or postmortem neuropathological examination). In multiple validation cohorts, plasma p-tau217 differentiates neuropathologically confirmed Alzheimer's disease and amyloid PET positivity with very high diagnostic accuracy (AUCs ranging from 0.89 to 0.97).
- supports: Discriminative Accuracy of Plasma Phospho-tau217 for Alzheimer Disease vs Other Neurodegen… (JAMA 2020) · cited 1627x in the literature
"In cohort 1, antemortem plasma P-tau217 differentiated neuropathologically defined AD from non-AD (area under the curve [AUC], 0.89 [95% CI, 0.81-0.97]) with significantly higher accuracy than plasma P-tau181 and neurofilament light chain (NfL)... In cohort 2, plasma P-tau217 discriminated abnormal vs normal tau-PET scans (AUC, 0.93 [95% CI, 0.91-0.96])" (abstract, results, passage verified)
pubmedfull study (doi) - supports: Highly accurate blood test for Alzheimer's disease is similar or superior to clinical cere… (Nature medicine 2024) · cited 440x in the literature
"Plasma %p-tau217 was clinically equivalent to FDA-approved CSF tests in classifying Aβ PET status, with an area under the curve (AUC) for both between 0.95 and 0.97. Plasma %p-tau217 was generally superior to CSF tests in classification of tau-PET with AUCs of 0.95-0.98." (abstract, results, passage verified)
pubmedfull study (doi) - supports: Blood Biomarkers to Detect Alzheimer Disease in Primary Care and Secondary Care. (JAMA 2024) · cited 370x in the literature
"In both the primary care and secondary care assessments, 50% of patients had AD pathology... In the overall population, the diagnostic accuracy using the APS2 (90% [95% CI, 88%-92%]) was not different from the diagnostic accuracy using the percentage of p-tau217 alone (90% [95% CI, 88%-91%])." (abstract, results)
pubmedfull study (doi)
A biomarker profile of normal p-tau, normal GFAP, and elevated neurofilament light (NfL) in blood is commonly associated with frontotemporal dementia.
"for example, if you've got a normal p-tau, a normal GFAP, but a high NfL, the first concern is frontotemporal dementia. That is a common one to give you that pattern." (said at 0:26:12)
Blood-based biomarker profiling demonstrates that the combination of normal phosphorylated tau (p-tau), normal glial fibrillary acidic protein (GFAP), and elevated neurofilament light chain (NfL) is characteristic of frontotemporal dementia (FTD). In clinical differential diagnosis panels, elevated p-tau and GFAP are hallmarks of Alzheimer's disease pathology (amyloid- and tau-related astrogliosis and phosphorylation), whereas FTD typically exhibits non-elevated p-tau and GFAP alongside marked neuroaxonal injury reflected by elevated plasma NfL.
- supports: Differential diagnostic performance of a panel of plasma biomarkers for different types of… (Alzheimer's & dementia (Amsterdam, Netherlands) 2022) · cited 89x in the literature
"The Simoa panel that optimally differentiated AD from FTD consisted of NfL and p-tau181 (area under the curve [AUC] = 0.94; cohort 1) or NfL, GFAP, and p-tau181 (AUC = 0.90; cohort 2)." (abstract, results, passage verified)
pubmedfull study (doi) - supports: Development of thresholds and a visualization tool for use of a blood test in routine clin… (Alzheimer's & dementia : the journal of the Alzheimer's Association 2024) · cited 23x in the literature
"P-tau181, GFAP, and NfL were selected. This combination had area under the curve (AUC) = 83% to identify amyloid positivity in pre-dementia stages, AUC = 87%-89% to differentiate Alzheimer's or controls from frontotemporal dementia, AUC = 74%-76% to differentiate Alzheimer's or controls from dementia with Lewy bodies." (abstract, results, passage verified)
pubmedfull study (doi) - supports: Blood-based multimodal biomarker models for differentiating early-onset Alzheimer's diseas… (Journal of neurology 2026)
"P-tau levels were higher in patients with EOAD, whereas NfL levels were higher in EOFTD and were elevated in those with EOAD participants with severe hippocampal atrophy. Adding NfL, GFAP, and APOE ε4 status further improved the discriminative accuracy for differentiating EOAD from EOFTD." (abstract, results, passage verified)
pubmedfull study (doi)
In rodent models of Alzheimer's disease, microglial activity is required for beta-amyloid-mediated synapse loss and neuropathology.
"And in the rodent research, the microglial activity is fundamental for the pathological effects of the beta-amyloid. You know, when these mice are genetically selected with high levels of beta-amyloid, the real pathology, the real digestion of synapses, etc., that happens really is microglia-dependent" (said at 0:17:31)
Rodent models of Alzheimer's disease demonstrate that microglial activation and phagocytosis, mediated by the classical complement cascade (C1q, C3, and CR3), are required for beta-amyloid-induced synapse elimination and dendritic spine loss. Inhibiting microglial complement receptors or depleting microglia pharmacologically rescues synaptic spine loss and neuronal death in amyloid-accumulating mouse models (such as APP/PS1 and 5xFAD) without significantly altering amyloid-beta plaque burden. Because the supporting evidence is derived entirely from animal models, the GRADE certainty is rated as very low.
- supports: Eliminating microglia in Alzheimer's mice prevents neuronal loss without modulating amyloi… (Brain : a journal of neurology 2016) · cited 744x in the literature
"Ten-month-old 5xfAD mice were treated with a selective CSF1R inhibitor for 1 month, resulting in the elimination of ∼80% of microglia. Chronic microglial elimination does not alter amyloid-β levels or plaque load; however, it does rescue dendritic spine loss and prevent neuronal loss in 5xfAD mice, as well as reduce overall neuroinflammation." (abstract, results, passage verified)
pubmedfull study (doi) - supports: Complement and microglia mediate early synapse loss in Alzheimer mouse models. (Science (New York, N.Y.) 2016) · cited 3458x in the literature
"Here we show in mouse models that complement and microglia mediate synaptic loss early in AD... Inhibition of C1q, C3, or the microglial complement receptor CR3 reduces the number of phagocytic microglia, as well as the extent of early synapse loss. C1q is necessary for the toxic effects of soluble β-amyloid (Aβ) oligomers on synapses and hippocampal long-term potentiation. Finally, microglia in adult brains engulf synaptic material in a CR3-dependent process when exposed to soluble Aβ oligomers." (abstract, results)
pubmedfull study (doi)
Phosphorylation of the tau protein alters its charge and conformation, causing it to dissociate from microtubules and leading to neurite collapse.
"This same molecule, when you now have insults and you're now switching to protection mode, becomes phosphorylated, which changes its charge and changes its shape. It pops off the microtubules, which now allows the neurites to collapse" (said at 0:23:26)
Biophysical and computational modeling studies demonstrate that phosphorylation of the tau protein introduces negative electrostatic charges and induces distinct conformational changes. These changes alter the microtubule-binding region, reducing tau's affinity for tubulin and promoting its dissociation from microtubules, which destabilizes the neuronal cytoskeleton and contributes to neurite retraction and collapse.
- supports: The Role of Post-Translational Modifications on the Structure and Function of Tau Protein. (Journal of molecular neuroscience : MN 2022) · cited 74x in the literature
"Involving addition of chemical groups or protein units to specific residues of the target protein, post-translational modifications (PTMs) alter the charge, hydrophobicity, and conformation of a protein, which in tune influences protein function, protein - protein interaction, and protein aggregation." (abstract, background, passage verified)
pubmedfull study (doi) - supports: Acetylation and phosphorylation processes modulate Tau's binding to microtubules: A molecu… (Biochimica et biophysica acta. General subjects 2023) · cited 17x in the literature
"Our in silico findings demonstrated that the electrostatic changes, due to the absence of positive Lys' charges in acetylation cases, or the increasingly negative charge in the phosphorylated forms, hamper the association to the MT tubulins in most cases. Post-translational modifications also pose very distinct conformations to the ones described for native Tau, which hinders the microtubule-binding region (MTBR) and turns difficult the expected binding." (abstract, results, passage verified)
pubmedfull study (doi)
Glial fibrillary acidic protein (GFAP) is an intermediate filament protein whose levels in blood elevate during reactive astrogliosis and brain inflammation.
"And that is glial fibrillary acidic protein that is an intermediate filament protein. So what happens when your astrocytes that are supporting your neurons now balloon up and start to react because you're in inflammation mode or because you are trying to do some rebuilding, they essentially, like the Hulk, they boom, they hyperactivate. And when they do that, they are building with GFAP, so they've got to have that as a protein that now goes up. You can again pick that up in the blood." (said at 0:25:09)
Glial fibrillary acidic protein (GFAP) is a type III intermediate filament protein predominantly expressed in astrocytes. During reactive astrogliosis triggered by central nervous system injury, inflammation, or neurodegeneration, astrocytes upregulate GFAP expression, and GFAP is subsequently released into biofluids (including blood/plasma/serum), where it serves as a well-established biomarker of astrocyte activation.
- supports: Glial fibrillary acidic protein: from intermediate filament assembly and gliosis to neurob… (Trends in neurosciences 2015) · cited 1070x in the literature
"Glial fibrillary acidic protein (GFAP) is an intermediate filament (IF) III protein uniquely found in astrocytes in the central nervous system (CNS), non-myelinating Schwann cells in the peripheral nervous system (PNS), and enteric glial cells... GFAP gene activation and protein induction appear to play a critical role in astroglial cell activation (astrogliosis) following CNS injuries and neurodegeneration. Emerging evidence also suggests that, following traumatic brain and spinal cord injuries and stroke, GFAP and its breakdown products are rapidly released into biofluids, making them strong candidate biomarkers for such neurological disorders." (abstract, passage verified)
pubmedfull study (doi) - supports: Glial fibrillary acidic protein in Alzheimer's disease: a narrative review. (Brain communications 2024) · cited 75x in the literature
"Glial fibrillary acidic protein (GFAP), a type III intermediate filament protein predominantly expressed in astrocytes, has emerged as a key biomarker for monitoring this response. During astrogliosis, GFAP is released into biofluids, making it a candidate for non-invasive diagnosis and tracking of neurodegenerative diseases." (abstract, passage verified)
pubmedfull study (doi)
Poor glucose utilization in the temporal and parietal regions on PET scan is a hallmark of Alzheimer's disease.
"And when you look at a PET scan, that's what you see, poor glucose utilization in the temporal and parietal region. That's the hallmark of Alzheimer's disease." (said at 0:35:10)
Positron emission tomography using 18F-fluorodeoxyglucose (FDG-PET) measures regional cerebral glucose metabolism. A distinct pattern of reduced glucose utilization (hypometabolism) in the temporoparietal regions of the brain is an established diagnostic hallmark of typical Alzheimer's disease.
Research by Mary Newport and Stephen Cunnane demonstrates that exogenous ketones are beneficial for individuals with mild cognitive impairment.
"So at the beginning, we just give exogenous ketones, and as people like Mary Newport and Stephen Cunnane have shown, that is helpful for people even with MCI." (said at 0:35:45)
Published clinical research by Stephen Cunnane and colleagues, as well as work by Mary Newport, supports the claim that exogenous ketogenic supplementation can benefit brain energetics and cognitive function in cognitive impairment and mild cognitive impairment (MCI). In a 6-month randomized controlled trial led by Cunnane's team (Fortier et al., 2021), a ketogenic medium-chain triglyceride (kMCT) drink significantly improved memory recall, verbal fluency, naming, and executive processing speed in individuals with MCI compared to placebo. Newport and colleagues previously reported case-based clinical and functional improvements following administration of a ketone monoester in Alzheimer's disease.
- supports: A new way to produce hyperketonemia: use of ketone ester in a case of Alzheimer's disease. (Alzheimer's & dementia : the journal of the Alzheimer's Association 2015) · cited 195x in the literature
"The patient improved markedly in mood, affect, self-care, and cognitive and daily activity performance. The KME was well tolerated throughout the 20-month treatment period." (abstract, results, passage verified)
pubmedfull study (doi) - supports: A ketogenic drink improves brain energy and some measures of cognition in mild cognitive i… (Alzheimer's & dementia : the journal of the Alzheimer's Association 2019) · cited 214x in the literature
"A dose of 30 g/day of kMCT taken for 6 months bypasses a significant part of the brain glucose deficit and improves several cognitive outcomes in MCI." (abstract, conclusions, passage verified)
pubmedfull study (doi) - supports: A ketogenic drink improves cognition in mild cognitive impairment: Results of a 6-month RC… (Alzheimer's & dementia : the journal of the Alzheimer's Association 2021) · cited 186x in the literature
"Free and cued recall (Trial 1; P = .047), verbal fluency (categories; P = .024), Boston Naming Test (total correct answers; P = .033), and the Trail-Making Test (total errors; P = .017) improved significantly in the kMCT group compared to placebo (analysis of covariance; pre-intervention score, sex, age, education, and apolipoprotein E4 as covariates)." (abstract, results, passage verified)
pubmedfull study (doi)
Culturing primary brain cells in vitro requires insulin in the growth medium for neuronal survival.
"When, you know, when we used to grow brain cells in a dish in the lab, which we did for years and years, you had to always include insulin in their medium or they wouldn't survive. Insulin is such a crucial trophic factor for neurons." (said at 0:36:10)
Primary neuronal culture protocols (such as those using defined serum-free supplements like B-27 or N-2) universally require insulin or related trophic factors (such as IGF-1) to support long-term neuronal survival and metabolic support in vitro. Without insulin or cross-reacting insulin-family trophic factors in serum-free defined media, cultured primary neurons rapidly undergo apoptotic cell death.
Clinical trials show that magnesium L-threonate supplementation improves cognitive outcomes.
"I happen to like uh magnesium L-threonate for many people. Um, that and that one of the reasons I like that is because it's actually had trials, um things where there are data to actually show, yes, people did better with magnesium L-threonate." (said at 0:41:55)
Randomized, double-blind, placebo-controlled clinical trials support the claim that magnesium L-threonate supplementation improves cognitive outcomes. A 2016 trial (n=44) in adults aged 50–70 with cognitive impairment found significant improvements in overall cognitive ability and executive function with a magnesium L-threonate formulation compared to placebo. Subsequent randomized trials have shown similar benefits: a 2022 trial (n=109) reported significant improvements in memory quotient scores on the Clinical Memory Test in healthy adults, and a 2025 trial (n=100) demonstrated improvements in overall cognitive performance on the NIH Total Cognition Composite, working memory, and reaction time in adults aged 18–45. The overall evidence base is moderate in certainty due to relatively small sample sizes across individual trials.
- supports: Efficacy and Safety of MMFS-01, a Synapse Density Enhancer, for Treating Cognitive Impairm… (Journal of Alzheimer's disease : JAD 2016) · cited 58x in the literature
"With MMFS-01 treatment, overall cognitive ability improved significantly relative to placebo (p = 0.003; Cohen's d = 0.91). Cognitive fluctuation was also reduced. The study population had more severe executive function deficits than age-matched controls from normative data and MMFS-01 treatment nearly restored their impaired executive function, demonstrating that MMFS-01 may be clinically significant." (abstract, results, passage verified)
pubmedfull study (doi) - supports: The effects of magnesium L-threonate (Magtein ® ) on cognitive performance and sleep quali… (Frontiers in nutrition 2025) · cited 1x in the literature
"Compared to the placebo, Magtein ® was associated with greater improvements in overall cognitive performance as measured by the NIH Total Cognition Composite ( p = 0.043), with larger treatment effects on working and episodic memory. There was also a 7.5-year reduction in estimated brain cognitive age and a greater improvement in reaction time ( p = 0.031)." (abstract, results, passage verified)
pubmedfull study (doi)
Studies show a reduced risk of developing Alzheimer's disease over 3 years in people using semaglutide compared to other antidiabetic agents, with the largest contrast against insulin in type 2 diabetics.
"We're seeing uh initial reports of reduced risk of development of Alzheimer's over a 3-year period of time in individuals using semaglutide, Ozempic, uh in comparison to other antidiabetic agents. And the largest difference was in comparison to the use of insulin in a type 2 diabetic." (said at 0:48:35)
A large target trial emulation study using electronic health records from over 1 million patients with type 2 diabetes (Wang et al., 2024) evaluated the incidence of first-time Alzheimer's disease diagnosis over a 3-year follow-up period. The study found that semaglutide was associated with a significant 40% to 70% reduction in risk of first-time Alzheimer's disease diagnosis compared to other antidiabetic medications, with the greatest risk reduction observed when compared to insulin (hazard ratio 0.33, 95% CI: 0.21 to 0.51). Because these findings are from observational real-world data rather than randomized controlled trials, the certainty of the evidence is low.
Head-to-head clinical comparisons show that GLP-1 receptor agonists outperform Januvia (sitagliptin).
"Of course now they've gone head-to-head Januvia with GLP-1, and the GLP-1s outperform Januvia." (said at 0:51:15)
A systematic review and meta-analysis of head-to-head randomized controlled trials confirms that GLP-1 receptor agonists are significantly more effective than sitagliptin (Januvia) in lowering glycated hemoglobin (HbA1c) and reducing body weight in adults with type 2 diabetes.
A clinical trial evaluating intranasal insulin for Alzheimer's disease or cognitive decline failed to meet its primary efficacy endpoints.
"This is the same thing as, you know, several years ago there was a trial where they tried intranasal insulin. It sounded so good: 'Let's get insulin into the brain.' Well, the problem is you may be creating—and that trial failed unfortunately" (said at 0:52:00)
A major multi-site Phase 2/3 randomized controlled trial (the SNIFF trial, NCT01767909) evaluating intranasal insulin (40 IU daily) versus placebo over 12 months in 289 adults with mild cognitive impairment or Alzheimer disease dementia failed to meet its primary efficacy endpoint. In the primary intention-to-treat analysis (n = 240), there was no statistically significant difference between intranasal insulin and placebo on the primary outcome, the Alzheimer's Disease Assessment Scale-Cognitive Subscale (ADAS-Cog-12; difference 0.0258 points; 95% CI, -1.771 to 1.822; P = .98), nor were there differences in secondary clinical or cerebrospinal fluid outcomes.
Amyloid-beta disrupts insulin signaling by interfering with the insulin receptor and its substrate IRS-1.
"If you look at the insulin receptor and then its interaction with IRS-1, its major signaling molecule, guess what interferes with that insulin signaling? Amyloid." (said at 0:52:55)
Preclinical models and human brain tissue studies demonstrate that amyloid-beta (Aβ) oligomers disrupt neuronal insulin signaling by triggering stress kinases such as JNK, which induces inhibitory serine phosphorylation of insulin receptor substrate-1 (IRS-1) and blocks normal insulin signaling downstream of the insulin receptor.
Metformin activates AMPK by inhibiting ATP production through the mitochondrial respiratory chain.
"The way it triggers your kinase is by preventing you from making the ATP that would normally inhibit that. So what you're really doing is you're saying, 'Okay, you're eating, you're trying to do everything to get more energetics, but I'm going to block that so that you'll have more AMP and you'll now activate your AMP kinase.'" (said at 0:54:58)
The speaker's description matches the widely recognized canonical mechanism of metformin. Metformin inhibits Complex I (NADH:ubiquinone oxidoreductase) of the mitochondrial respiratory chain, reducing cellular ATP synthesis and thereby increasing the cellular AMP:ATP (and ADP:ATP) ratio, which promotes the allosteric activation and phosphorylation of AMP-activated protein kinase (AMPK).
MPTP is converted into toxic MPP+ by monoamine oxidase B, and MPP+ is selectively transported into dopaminergic neurons of the substantia nigra via the dopamine transporter.
"MPTP... is metabolized to MPP+ and then becomes an issue. So the question is why just those cells, the dopaminergic neurons in the pars compacta of substantia nigra, why do they suffer? And, you know, I wondered about that for a while, and I learned that it is selectively transported into the neuron by the dopamine transporter, A; and B, that the conversion of MPTP to become the toxic MPP+ requires monoamine oxidase type B" (said at 0:56:58)
The speaker's statement accurately describes the established biochemical mechanism of MPTP (1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine) neurotoxicity. In the brain (primarily in glial cells), MPTP is bioactivated and oxidized by monoamine oxidase B (MAO-B) into the toxic metabolite MPP+ (1-methyl-4-phenylpyridinium). MPP+ is then selectively taken up into dopaminergic neurons of the substantia nigra pars compacta via the plasma membrane dopamine transporter (DAT), where it accumulates and inhibits mitochondrial complex I, leading to selective dopaminergic neuronal death.
- supports: Spinal cord degeneration in C57BL/6N mice following induction of experimental parkinsonism… (Journal of neurochemistry 2008) · cited 26x in the literature
"Mitochondrial enzyme monoamine oxidase-B (MAO-B) responsible for in vivo conversion of MPTP to MPP+ was inhibited in SC by pre-treatment with l-deprenyl, a specific inhibitor of MAO-B." (abstract, results, passage verified)
pubmedfull study (doi) - supports: Combined 1-Deoxynojirimycin and Ibuprofen Treatment Decreases Microglial Activation, Phago… (Journal of neuroimmune pharmacology : the official journal of the Society on NeuroImmune Pharmacology 2021) · cited 42x in the literature
"MPTP (1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine) is a protoxicant that, after crossing the Blood Brain Barrier, is metabolized by astrocytic MAO-B to MPDP+, a pyridinium intermediate, which undergoes further two-electron oxidation to yield the toxic metabolite MPP+ (methyl-phenyltetrahydropyridinium) that is then selectively transported into nigral neurons via the mesencephalic dopamine transporter." (abstract, graphical abstract summary, passage verified)
pubmedfull study (doi)
Maneb and mancozeb are fungicides that act as mitochondrial toxins.
"Maneb and mancozeb being fungicides that are still sold online, which are mitochondrial toxins, to be used on our vegetable gardens." (said at 0:59:54)
Maneb and mancozeb are manganese- and zinc-containing ethylene-bis-dithiocarbamate (EBDC) fungicides widely demonstrated in cellular and isolated mitochondrial models to act as mitochondrial toxins. In vitro and animal studies show that exposure to both maneb and mancozeb impairs mitochondrial function by inhibiting electron transport chain complexes (including NADH-linked respiration and complex I-V activity), causing mitochondrial membrane depolarization, uncoupling oxidative phosphorylation, depleting cellular ATP, and triggering reactive oxygen species generation.
Exposure to organic toxicants such as trichloroethylene (TCE), perchloroethylene (PCE), dieldrin, and paraquat contributes to the risk and pathology of Parkinson's disease.
"I would mention, as you know, the common things that are driving this in that particular network are the organic toxicants. You mentioned MPP+, MPTP, but it's the things like trichloroethylene and perchloroethylene and dieldrin and paraquat" (said at 0:59:33)
Extensive epidemiological and mechanistic literature supports the link between exposure to organic toxicants—including industrial solvents like trichloroethylene (TCE) and perchloroethylene (PCE), as well as pesticides like paraquat and dieldrin—and an increased risk and hallmark pathology of Parkinson's disease. These agents trigger neurotoxic pathways including mitochondrial complex I inhibition, oxidative stress, neuroinflammation, and selective dopaminergic neuron degeneration in the substantia nigra.
- supports: Elucidating Conserved Transcriptional Networks Underlying Pesticide Exposure and Parkinson… (Frontiers in genetics 2018) · cited 45x in the literature
"Epidemiological evidence suggests that occupational exposure to pesticides (e.g., dieldrin, paraquat, rotenone, maneb, and ziram) is associated with a higher risk of developing PD in susceptible populations. Within dopaminergic neurons, environmental chemicals can have an array of adverse effects resulting in cell death, such as aberrant redox cycling and oxidative damage, mitochondrial dysfunction, unfolded protein response, ubiquitin-proteome system dysfunction, neuroinflammation, and metabolic disruption." (abstract, passage verified)
pubmedfull study (doi) - supports: Impact of Environmental Risk Factors on Mitochondrial Dysfunction, Neuroinflammation, Prot… (International journal of molecular sciences 2022) · cited 104x in the literature
"Numerous epidemiological studies during the past two decades have shown positive associations between PD and several environmental factors, including exposure to neurotoxic pesticides/herbicides and heavy metals as well as traumatic brain injury... specifically 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP), rotenone, paraquat (PQ), dichloro-diphenyl-trichloroethane (DDT), dieldrin, manganese (Mn), and vanadium (V)." (abstract, passage verified)
pubmedfull study (doi) - supports: Environmental toxicants and Parkinson's disease: recent evidence, risks, and prevention op… (The Lancet. Neurology 2025) · cited 35x in the literature
"Increasing evidence implicates three classes of toxicants-certain pesticides, the dry-cleaning chemicals trichloroethylene and perchloroethylene, and air pollution-in the development of Parkinson's disease. These toxicants are widely prevalent, impair mitochondrial or lysosomal function, or both, and contribute to, if not cause, the disease." (abstract, passage verified)
pubmedfull study (doi)
Amyotrophic lateral sclerosis (ALS) occurs more frequently in men than in women.
"We've got men getting more ALS and men getting more Parkinson's." (said at 0:58:00)
Epidemiological evidence consistently demonstrates that amyotrophic lateral sclerosis (ALS) has a higher incidence in men than in women. A systematic review and meta-analysis of 39 population-based studies found a pooled male-to-female standardized incidence ratio of 1.35 (95% CI 1.31–1.40), confirming a higher risk in men across age groups.
Nitric oxide is fundamental for insulin functionality.
"and I think, you know, we recognize nitric oxide is important for perfusion, for blood supply, but also fundamental for insulin functionality." (said at 0:53:30)
The statement that nitric oxide is important for blood supply/perfusion and fundamental for insulin functionality is supported by physiological literature. Insulin signaling stimulates endothelial nitric oxide synthase (eNOS) to produce nitric oxide (NO), promoting vasodilation and capillary recruitment. This NO-mediated vascular response accounts for an estimated 25% to 40% of insulin-stimulated glucose disposal by facilitating the delivery of insulin and glucose to target tissues such as skeletal muscle.
Estradiol binding to its receptor upregulates alpha-secretase, which cleaves APP to promote non-amyloidogenic processing.
"estradiol binds to its receptor, enters the nucleus, of course affects hundreds of genes. One of the things that it turns up is the alpha-secretase that cleaves the APP to give you the connection, to give you that supportive side." (said at 1:01:07)
Preclinical in vitro and rodent studies support the mechanism described by the speaker. 17β-estradiol acting through estrogen receptors promotes the non-amyloidogenic pathway of amyloid precursor protein (APP) processing by upregulating α-secretase activity (specifically ADAM10), increasing neuroprotective soluble APPα (sAPPα) and decreasing amyloid-beta (Aβ42) accumulation. Because the evidence is derived primarily from animal and cellular models, the GRADE certainty is very low.
Complement C3 marks synapses for microglial phagocytosis/digestion, and synaptic binding of C3 is reduced by estradiol.
"estradiol helps reduce the binding to synapses of C3. Complement C3 labels synapses such that they are then primed for digestion from the microglial cells, and that's reduced with the presence of estradiol." (said at 1:02:11)
Preclinical and mechanistic studies support both parts of the claim. The classical complement cascade, specifically complement component C3 and its receptor CR3 on microglia, opsonizes (marks) synapses for microglial engulfment and phagocytosis during both normal development and neurodegenerative pathology. Furthermore, research demonstrates that normal levels of β-estradiol protect against this pathway: falling estradiol levels promote aberrant S-nitrosylation of C3 (SNO-C3), which enhances C3 binding and downstream microglial phagocytosis of synapses. However, because evidence for this regulatory mechanism is based on postmortem human brain tissue, animal models, and in vitro studies, the GRADE certainty is very low.
In Alzheimer's disease brains, C3-bound synapses show a 5-fold increase in men and up to a 28-fold increase in women compared to controls.
"in Alzheimer's brains, in men, there's a five-fold increase of the C3-bound synapses, and in women, it's as much as a 28-fold increase in the Alzheimer's women of that C3 binding to the synapse to label it for digestion." (said at 1:02:25)
A 2022 postmortem and mechanistic study published in Science Advances (Yang et al., PMID 36516243) examined S-nitrosylated complement component 3 (SNO-C3) and complement-mediated synaptic elimination in human Alzheimer's disease (AD) and control brains. The authors demonstrated that complement C3 activation and synaptic binding/tagging for microglial phagocytosis are markedly elevated in AD brains in a sex-dependent manner, with female AD brains exhibiting a much larger increase (up to ~28-fold higher SNO-C3/synaptic targeting) compared to male AD brains (~5 to 6-fold increase). Because evidence is derived from postmortem human brain tissue and laboratory mechanistic models, overall certainty is low.
Brain metabolic changes detectable by fluorodeoxyglucose (FDG) PET occur in people's 30s and 40s, preceding Alzheimer's cognitive symptoms by two to three decades.
"the metabolic changes that you can see on the type of scan you mentioned earlier, these fluorodeoxyglucose PET scans demonstrating brain metabolism, are happening in people's 30s and 40s, presaging the cognitive manifestations by two to three decades." (said at 1:03:44)
Published neuroimaging research supports the claim that fluorodeoxyglucose positron emission tomography (FDG-PET) can detect cerebral metabolic changes decades before the onset of Alzheimer's dementia symptoms. In a landmark comparative study of young adults aged 20 to 39, cognitively normal carriers of the APOE ε4 susceptibility allele showed significantly reduced rates of cerebral glucose metabolism in the posterior cingulate, parietal, temporal, and prefrontal cortices—the same regions characteristically affected in Alzheimer's disease—roughly two to three decades before potential clinical presentation. Subsequent studies have confirmed similar presymptomatic regional hypometabolism in middle-aged and genetic-risk cohorts.
- supports: Functional brain abnormalities in young adults at genetic risk for late-onset Alzheimer's … (Proceedings of the National Academy of Sciences of the United States of America 2004) · cited 985x in the literature
"Like previously studied patients with probable AD and late-middle-aged epsilon4 carriers, the young epsilon4 carriers had abnormally low rates of glucose metabolism bilaterally in the posterior cingulate, parietal, temporal, and prefrontal cortex. Carriers of a common Alzheimer's susceptibility gene have functional brain abnormalities in young adulthood, several decades before the possible onset of dementia." (abstract, results, passage verified)
pubmedfull study (doi) - supports: Correlations between apolipoprotein E epsilon4 gene dose and brain-imaging measurements of… (Proceedings of the National Academy of Sciences of the United States of America 2005) · cited 400x in the literature
"We previously found that cognitively normal late-middle-aged APOE epsilon4 carriers have abnormally low CMRgl in the same brain regions as patients with probable Alzheimer's dementia. In a PET study of 160 cognitively normal subjects 47-68 years of age, including 36 epsilon4 homozygotes, 46 heterozygotes, and 78 epsilon4 noncarriers who were individually matched for their gender, age, and educational level, we now find that epsilon4 gene dose is correlated with lower CMRgl in each of these brain regions." (abstract, results, passage verified)
pubmedfull study (doi)
Expressing human Alzheimer's genes in Drosophila fruit flies generated an ADHD-like phenotype with hyperactivity that responded to dextroamphetamine.
"When we put human Alzheimer genes into fruit flies, guess what? They didn't get Alzheimer's, they got ADHD. And this is published. They fit all criteria. They were more in males. It was treated by the same drugs like dextroamphetamine beautifully. They had increased movement all the time." (said at 1:06:17)
A 2015 study published in the Journal of Neurology & Neurophysiology reported that an invertebrate Drosophila melanogaster Alzheimer's model exhibited features analogous to attention deficit hyperactivity disorder (ADHD), including hyperactivity, male predominance, and a reversible response to dextroamphetamine. Because the evidence is derived solely from an animal (invertebrate) model in a single preliminary report, the certainty of evidence for human clinical implications is very low.
Published scientific research demonstrates a relationship between ADHD and an increased risk of cognitive decline.
"And there's more and more work, as you know, published about the relationship between ADHD and cognitive decline." (said at 1:06:37)
Published systematic reviews and observational cohort studies demonstrate a significant association between attention-deficit/hyperactivity disorder (ADHD) and an increased risk of subsequent cognitive decline and dementia. A meta-analysis of cohort and case-control studies found that individuals with ADHD had a significantly elevated hazard of developing all-cause dementia (pooled HR 2.52, 95% CI 1.51–4.22). While observational data show a clear link, researchers note that additional prospective studies are required to determine the exact direct causal mechanisms.
Unverified means no publication matching the claim was located; it does not prove the claim false. Spotted an error? See the corrections policy - disputes from the people quoted are prioritized.